Lazard Asset Management’s BioAtla BCAB Stock Holding History

Lazard Asset Management’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-84	Closed	-$2K	–	2309
2024 Q4	$2K	Buy	+84	New	+$7.05K	﹤0.01%	2178

Other funds holding BCAB

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Lazard Asset Management's BCAB Position: Q1 2025 in Review

Lazard Asset Management sold out of BioAtla (BCAB) in Q1 2025, closing a stake of 84 shares — an estimated $2K sold.

Lazard Asset Management first reported a position in BCAB in Q4 2024 and held it in 1 quarter. The position peaked at $2K in Q4 2024. 41 funds tracked by Wall St. Rank hold BCAB as of Q1 2025.

Lazard Asset Management reported no remaining BioAtla position as of Q1 2025 after selling out during the quarter.
Lazard Asset Management sold 84 BioAtla shares in Q1 2025, an estimated $2K.
Lazard Asset Management first reported a position in BioAtla in Q4 2024 and held it in 1 quarter.
Lazard Asset Management's BioAtla position peaked at $2K in Q4 2024.
41 funds tracked by Wall St. Rank held BioAtla as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.